Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | Fc1ccc(cc1)C1(CC(=O)N2CC(C2)C#N)C2CC3CC(C2)CC1C3 |TLB:25:24:22:18.19.20,8:7:18.25.19:23.21.22,4:7:22:18.19.20,THB:25:19:7.24.23:22,20:19:7:23.21.22,20:21:7:18.25.19,8:7:22:18.19.20,4:7:18.25.19:23.21.22,(54.09,-42.35,;54.11,-40.81,;52.78,-40.02,;52.8,-38.49,;54.14,-37.74,;55.46,-38.51,;55.45,-40.04,;54.16,-36.2,;53.02,-35.16,;51.55,-35.64,;50.3,-34.73,;51.06,-37.11,;49.69,-37.8,;50.39,-39.18,;51.77,-38.48,;49.91,-40.65,;49.43,-42.11,;55.36,-34.92,;56.68,-35.41,;58.08,-35.06,;58.1,-33.53,;56.69,-32.96,;55.35,-33.43,;55.65,-34.19,;55.65,-35.78,;57.07,-36.34,)| |